Randomized trial · people

Amycretin: 24.3% weight loss at 36 weeks in a phase 1b/2a trial

Checked against the paper Randomized trialPublished by PepVault

The takeaway

Early human data show weekly amycretin shots lowered body weight in a dose-related way over up to 36 weeks, with mostly mild to moderate gut side effects; larger and longer trials are still needed.

Kind
Randomized trial
Studied in
People
Number studied
125
Published
2025
Journal
Lancet

What they tested

The team tested whether weekly amycretin injections were safe and well tolerated in people with overweight or obesity, how the drug moved through the blood (pharmacokinetics), and how much it changed body weight.

How the study was done

A randomized, double-blind, placebo-controlled phase 1b/2a trial at one US research center in 125 adults aged 18-55 with overweight or obesity (BMI 27.0-39.9 kg/m2). 101 got amycretin and 24 got placebo, a dummy shot, across five parts: a single-dose part and four parts where weekly doses were stepped up to 60 mg, 20 mg, 5 mg or 1.25 mg over 20 to 36 weeks.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking amycretin? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Body weight fell more with amycretin than with placebo in every multi-dose part. The change was -24.3% vs -1.1% in the 60 mg part at week 36, -22.0% vs 1.9% in the 20 mg part at week 36, -16.2% vs 2.3% in the 5 mg part at week 28, and -9.7% vs 2.0% in the 1.25 mg part at week 20. Stomach and bowel complaints led the side effect list; most were rated mild or moderate and had gone away by the study's end. A large share of people left the study, many of them for reasons other than side effects.

What it doesn’t show

This was a small, early-stage trial at a single site with only 24 people on placebo, many dropouts, and treatment lasting no longer than 36 weeks. It was funded by Novo Nordisk.

The paper

Dahl et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. Lancet. 2025.

The compound

More studies on Amycretin

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking amycretin? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo